Reducing insulin resistance with metformin: the evidence today (Q35539934)

8 August 2017

1 reference

title

Reducing insulin resistance with metformin: the evidence today (English)

0 references

1 reference

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S1262-3636(03)72785-2

12 March 2024

1 reference

https://api.crossref.org/works/10.1016/S1262-3636(03)72785-2

12 March 2024

author name string

R. Giannarelli

1

0 references

M. Aragona

2

0 references

A. Coppelli

3

0 references

S. Del Prato

4

0 references

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14502098

12 March 2024

publication date

1 September 2003

1 reference

full work available at URL

8 August 2017

September 2003

0 references

https://api.elsevier.com/content/article/PII:S1262363603727852?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1262-3636(03)72785-2

https://api.elsevier.com/content/article/PII:S1262363603727852?httpAccept=text/plain

12 March 2024

1 reference

https://api.crossref.org/works/10.1016/S1262-3636(03)72785-2

12 March 2024

published in

Diabetes and Metabolism

1 reference

8 August 2017

29

1 reference

8 August 2017

6S28-35

1 reference

8 August 2017

6S28-6S35

0 references

issue

4 Pt 2

1 reference

Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study

8 August 2017

4

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Insulin resistance: a chicken that has come to roost

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Insulin sensitivity and the risk of incident hypertension: insights from the Insulin Resistance Atherosclerosis Study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Measurement of insulin resistance in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Nuclear magnetic resonance studies of hepatic glucose metabolism in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Knockout models are useful tools to dissect the pathophysiology and genetics of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Insulin secretory function is impaired in isolated human islets carrying the Gly(972)-->Arg IRS-1 polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Mechanism by which metformin reduces glucose production in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Metformin and its liver targets in the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Modifications of citric acid cycle activity and gluconeogenesis in streptozotocin-induced diabetes and effects of metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

1 reference

7 January 2021

Effect of metformin treatment on insulin action in diabetic rats: in vivo and in vitro correlations.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Cellular mechanism of action of metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Mechanism of Action of Metformin: Insulin Receptor and Postreceptor Effects in Vitro and in Vivo*

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Metformin and fatty acids

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Inhibition of Carbohydrate-Induced Hypertriglyceridemia by Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Minireview: Secondary beta-cell failure in type 2 diabetes--a convergence of glucotoxicity and lipotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Metformin potentiates glucose-stimulated insulin secretion

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Lipotoxicity in human pancreatic islets and the protective effect of metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Role of AMP-activated protein kinase in mechanism of metformin action

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972785-2

7 January 2021

Metformin increases insulin-stimulated glucose transport in insulin-resistant human skeletal muscle

39

1 reference

https://api.crossref.org/works/10.1016/S1262-3636(03)72785-2

Effect of metformin on glucose metabolism in mouse soleus muscle

12 March 2024

40

1 reference

https://api.crossref.org/works/10.1016/S1262-3636(03)72785-2

Effect of metformin on insulin-stimulated tyrosine kinase activity of erythrocytes from obese women with normal glucose tolerance

12 March 2024

43

1 reference

https://api.crossref.org/works/10.1016/S1262-3636(03)72785-2

Current biochemical studies of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) suggest a new therapeutic approach

12 March 2024

52

1 reference

https://api.crossref.org/works/10.1016/S1262-3636(03)72785-2

AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes

12 March 2024

63

1 reference

https://api.crossref.org/works/10.1016/S1262-3636(03)72785-2

12 March 2024

Identifiers

0 references

1 reference